Article

The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile

2020-03-26

Abstract excerpt

<title>Abstract</title> <p>This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs* prescribed for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic or protein expression test. The study also aims to simplify patient access to approved targeted therapies that ar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: af71fa3c-91a7-566e-9959-ce9c79384cbd
DOI: 10.21203/rs.3.pex-622/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular ProfileDOI 10.21203/rs.3.pex-622/v1Read

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read

Pragmatic Nationwide Master Observational Trial Based on Genomic Alterations in Advanced Solid Tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II Study Protocol KCSG AL-22-09Semantic proximity Read

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncologySemantic proximity Read

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.Semantic proximity Read

A Comprehensive Tumor Molecular Profile Analysis in Clinical Practice: A Single Center’s ExperienceSemantic proximity Read

Overview of Molecular Diagnostics in Irish Clinical OncologySemantic proximity Read

Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databasesSemantic proximity Read

Next-Generation Sequencing-Based Evaluation of the Actionable Mutational Landscape in Solid Tumors: the “MOZART” Prospective Observational StudySemantic proximity Read

Overview of Molecular Diagnostics in Irish Clinical OncologySemantic proximity Read

MUSTARD-a comprehensive resource of mutation-specific therapies in cancer.Semantic proximity Read

Novel clinical trial designs emerging from the molecular reclassification of cancerSemantic proximity Read

Pharmacogenetics of anti-cancer drugs: State of the art and implementation – recommendations of the French National Network of PharmacogeneticsSemantic proximity Read